Ad
related to: dr thomas krivak oncology in tulsa texas a d t l transportation inc
Search results
Results From The WOW.Com Content Network
[8] [9] In 1999, the hospital was sold to Tulsa-based Hillcrest Medical Center, a locally owned non-profit organization, which already owned another hospital in Tulsa. [7] In 2004, the for-profit Ardent Health Services, also of Nashville, bought the Hillcrest system. [7]
Cancer Treatment Centers of America – Tulsa; Carl Albert Community Mental Health Center – McAlester Carnegie Tri-County Municipal Hospital – Carnegie, Oklahoma Cedar Ridge Hospital – Oklahoma City
CityPlex Towers, originally known as City of Faith Medical and Research in Tulsa, Oklahoma There are three triangular towers with over 2,200,000 square feet (200,000 m 2 ) of office space. [2] The tallest is the 60-story CityPlex Tower which at 648 feet (198 m) is the third tallest building in Oklahoma (after Devon Tower and BOK Tower ).
Robert Lawless served as the President of Texas Tech and Texas Tech Health Sciences Center from 1989-1996. He died on Aug. 10, 2024 at the age of 87.
Thomas E. Hutson is an American medical oncologist and cancer researcher based in Dallas, Texas. He is the director of Genitourinary Oncology Program and co-director of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center . [ 1 ]
A.C. Jackson was an African American surgeon who was murdered during the Tulsa race massacre in 1921 and is known as the most prominent victim of the massacre. Jackson was a leading member of the Oklahoma medical community and the African-American community in Tulsa, Oklahoma until his death.
Thomas Campbell Butler (born 1939 or 1940 [1]) is an American scientist specializing in infectious diseases including cholera and bubonic plague at Texas Tech University since 1987. He is credited with making oral hydration the standard treatment for diarrhea .
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients.